# Priyanka Sharma

Source: https://onco.cc/people/priyanka-sharma/  
OnCo record `priyanka-sharma` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Priyanka Sharma is a TNBC trialist testing whether anthracyclines can be dropped from pre-surgery treatment.

## Summary

Priyanka Sharma is Professor of Medicine at The University of Kansas Cancer Center and Study Chair of SWOG S2212 (SCARLET) within the SWOG Cancer Research Network. A breast medical oncologist specialising in triple-negative breast cancer, platinum chemotherapy and de-escalation trials, she led NeoSTOP and now leads SCARLET, which compares anthracycline-free carboplatin and docetaxel plus pembrolizumab with the KEYNOTE-522 regimen, testing whether anthracyclines can be dropped from pre-surgery treatment. Her papers report the NeoSTOP randomised phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin regimens in triple-negative breast cancer and a combined two-cohort analysis of neoadjuvant carboplatin plus docetaxel in the same disease.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Professor of Medicine, University of Kansas Cancer Center; Study Chair, SWOG S2212 (SCARLET)
- Specialisms: Triple-negative breast cancer; Platinum chemotherapy; De-escalation trials

## Sources

- SWOG leadership: https://www.swog.org/about/leadership
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Sharma%20P%5BAuthor%5D
- Google Scholar: https://scholar.google.com/scholar?q=Priyanka%20Sharma

## Connected records

- cancers: [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [SWOG Cancer Research Network](https://onco.cc/companies/swog/)
- institutions: [The University of Kansas Cancer Center](https://onco.cc/institutions/ku-cancer-center/)
- trials: [SCARLET (SWOG S2212)](https://onco.cc/trials/scarlet-s2212/)
- key papers: [Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-bardia-ascent-trop2-biomarker-ann-oncol-2021/), [ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease](https://onco.cc/key-papers/paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023/), [Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing](https://onco.cc/key-papers/paper-sharma-tnbc-registry-germline-brca-bcrt-2014/), [Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer](https://onco.cc/key-papers/paper-couch-tnbc-germline-17-genes-jco-2015/)

---
JSON: https://onco.cc/api/v1/entities/priyanka-sharma.json